Bioventus Q1 Sales Top Estimates by $2.3M, Reaching $132.1M
BVS sits 84% above its 52-week low of $5.81.
Summary
Bioventus reported first-quarter sales of $132.1 million, exceeding the IBES analyst estimate of $129.8 million. The company also posted adjusted EBITDA of $23.9 million for the quarter. This positive sales beat builds on the significant financial turnaround the company achieved in 2025, which included reaching GAAP net income and successfully refinancing debt, as highlighted in its recent 10-K filing. The better-than-expected revenue performance suggests continued operational strength and is likely to be a positive catalyst for the stock, especially given its current proximity to a 52-week high. Traders will now await the full earnings report for details on profitability and updated guidance.
At the time of this announcement, BVS was trading at $10.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $891M. The 52-week trading range was $5.81 to $10.76. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.